UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Effect of Interleukin-10 on Meningeal Inflammation in Experimental Bacterial Meningitis

The Journal of infectious diseases, 1997-11, Vol.176 (5), p.1239-1246

1997

Volltextzugriff (PDF)

Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome

The New England journal of medicine, 2019-11, Vol.381 (20), p.1918-1928

2019

Volltextzugriff (PDF)

Albendazole therapy for Microsporidium diarrhea in immunocompetent Costa Rican children

The Pediatric infectious disease journal, 2004-10, Vol.23 (10), p.915-918

2004

Volltextzugriff (PDF)

Overview of cefdinir: pharmacokinetics, safety, and efficacy in the treatment of uncomplicated skin and skin structure infections

Cutis (New York, N.Y.), 2004-05, Vol.73 (5 Suppl), p.14

2004

Volltextzugriff (PDF)

40666 Long-term Safety of Apremilast From a Pooled Analysis of 15 Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Oral Ulcers Associated With Behçet’s Syndrome

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB190-AB190

2023

Volltextzugriff (PDF)

Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial

Journal of the American Academy of Dermatology, 2022-01, Vol.86 (1), p.77-85

2022

Volltextzugriff (PDF)

Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study

Journal of the American Academy of Dermatology, 2020-07, Vol.83 (1), p.96-103

2020

Volltextzugriff (PDF)

Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial

Journal of the American Academy of Dermatology, 2024-06, Vol.90 (6), p.1232-1239

2024

Volltextzugriff (PDF)

42163 Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB122-AB122

2023

Volltextzugriff (PDF)

Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

Journal of the American Academy of Dermatology, 2020-02, Vol.82 (2), p.389-397

2020

Volltextzugriff (PDF)

16349 Rates of herpes zoster, hepatitis C, and tuberculosis among patients with psoriasis treated with apremilast, biologics, disease-modifying antirheumatic drugs, and corticosteroids: A cohort study in the US MarketScan database

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB61-AB61

2020

Volltextzugriff (PDF)

Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial

Journal of the American Academy of Dermatology, 2023-02, Vol.88 (2), p.430-433

2023

Volltextzugriff (PDF)

Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial

Journal of the American Academy of Dermatology, 2024-03, Vol.90 (3), p.485-493

2024

Volltextzugriff (PDF)

Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial

Clinical and Experimental Rheumatology, 2021-01, Vol.39 (5), p.80-87

2021

Volltextzugriff (PDF)

15144 Long-term safety of apremilast treatment in patients with psoriasis or psoriatic arthritis: Pooled analysis for 260 weeks and beyond in the ESTEEM 1 and 2 and PALACE 1-4 phase 3 trials

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB30-AB30

2020

Volltextzugriff (PDF)

Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media

The Pediatric infectious disease journal, 2004-09, Vol.23 (9), p.834-838

2004

Volltextzugriff (PDF)

Effect of interleukin-1 receptor antagonist and soluble tumor necrosis factor receptor in animal models of infection

The Journal of infectious diseases, 1995-01, Vol.171 (1), p.161-169

1995

Volltextzugriff (PDF)

Long-Term Safety of TAK-390MR, a PPI with a Novel Dual Delayed Release Formulation, in GERD Patients: 14

The American journal of gastroenterology, 2008-09, Vol.103, p.S5-S6

2008

Volltextzugriff (PDF)

Laryngeal tuberculosis

The Pediatric infectious disease journal, 1998-08, Vol.17 (8), p.758-760

1998

Volltextzugriff (PDF)

A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection

The Pediatric infectious disease journal, 2006-03, Vol.25 (3), p.211-218

2006

Volltextzugriff (PDF)

The Beneficial Effects of Early Dexamethasone Administration in Infants and Children with Bacterial Meningitis

The New England journal of medicine, 1991-05, Vol.324 (22), p.1525-1531

1991

Volltextzugriff (PDF)

Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis

The Pediatric infectious disease journal, 1993-03, Vol.12 (3), p.196-199

1993

Volltextzugriff (PDF)

A large, antigenically conserved protein on the surface of Moraxella catarrhalis is a target for protective antibodies

The Journal of infectious diseases, 1994-10, Vol.170 (4), p.867-872

1994

Volltextzugriff (PDF)

The limited role of pneumolysin in the pathogenesis of pneumococcal meningitis

The Journal of infectious diseases, 1995-09, Vol.172 (3), p.805-809

1995

Volltextzugriff (PDF)

A mutation affecting expression of a major outer membrane protein of Moraxella catarrhalis alters serum resistance and survival in vivo

The Journal of infectious diseases, 1993-11, Vol.168 (5), p.1194-1201

1993

Volltextzugriff (PDF)

1 – 25 von 161

Suche als RSS-Feed

Aktive Filter

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(155)
Mit Volltextzugriff
(112)

Publikationsform

Artikel
(159)
Tagungsberichte
(2)

Sprache

Englisch
(161)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The Effect of Interleukin-10 on Meningeal Inflammation in Experimental Bacterial Meningitis

Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome

Albendazole therapy for Microsporidium diarrhea in immunocompetent Costa Rican children

Overview of cefdinir: pharmacokinetics, safety, and efficacy in the treatment of uncomplicated skin and skin structure infections

40666 Long-term Safety of Apremilast From a Pooled Analysis of 15 Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Oral Ulcers Associated With Behçet’s Syndrome

Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial

Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study

Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial

42163 Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study

Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

16349 Rates of herpes zoster, hepatitis C, and tuberculosis among patients with psoriasis treated with apremilast, biologics, disease-modifying antirheumatic drugs, and corticosteroids: A cohort study in the US MarketScan database

Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial

Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial

Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial

15144 Long-term safety of apremilast treatment in patients with psoriasis or psoriatic arthritis: Pooled analysis for 260 weeks and beyond in the ESTEEM 1 and 2 and PALACE 1-4 phase 3 trials

Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media

Effect of interleukin-1 receptor antagonist and soluble tumor necrosis factor receptor in animal models of infection

Long-Term Safety of TAK-390MR, a PPI with a Novel Dual Delayed Release Formulation, in GERD Patients: 14

Laryngeal tuberculosis

A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection

The Beneficial Effects of Early Dexamethasone Administration in Infants and Children with Bacterial Meningitis

Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis

A large, antigenically conserved protein on the surface of Moraxella catarrhalis is a target for protective antibodies

The limited role of pneumolysin in the pathogenesis of pneumococcal meningitis

A mutation affecting expression of a major outer membrane protein of Moraxella catarrhalis alters serum resistance and survival in vivo

Aktive Filter

Suchergebnisse filtern